Adherence research across chronic disease has pointed in the same direction for decades: as the number of required events per period rises, the share of patients who complete them falls. A weekly cadence asks for roughly 52 acts of compliance a year. A twice-daily one asks for more than 700. The medication can be identical in effect and the lived experience is not comparable.
KFF’s March 2026 polling found that about 18 percent of US adults have taken a GLP-1 medication and 12 percent were taking one at the time of the survey. Those adoption figures exist partly because the cadence made sustained use realistic for people who would not have sustained a daily regimen.
Why weekly works differently from daily
A daily medication has to attach itself to an existing routine to survive. It rides on brushing teeth, or breakfast, or a bedside table. When the routine breaks, which it does on holiday, during illness, after a house move or a shift change, the medication breaks with it. Daily regimens fail at the seams of ordinary life.
A weekly medication cannot ride on a daily routine because there is no daily anchor to attach to. It has to become its own event, and that turns out to be a more durable arrangement. A recurring weekly commitment is something a person plans around rather than something that depends on an unbroken chain of small habits.
Weekly cadence also changes the consequence of a lapse. Forgetting a daily medication is a frequent, low-salience event that normalises quickly; a patient who misses several doses often drifts out of treatment without ever deciding to stop. A weekly event is harder to miss unnoticed, and noticing is what creates the opportunity to resume.
The pharmacokinetic reason it is possible
This cadence is not a convenience choice layered on top of a molecule. It is a property engineered into it. These compounds are modified so that they persist in circulation far longer than the natural hormones they are modelled on, which would otherwise be cleared within minutes.
The resulting profile is also steadier. A daily medication produces a sawtooth of peaks and troughs; a long-acting weekly one produces something flatter. Patients frequently describe the effect as more even, without the pronounced on-and-off quality of shorter-acting drugs. Specific regimens are set by a prescriber for the individual patient, and the written guidance supplied with a prescription is the authority on how a particular preparation is used.
Where the weekly rhythm still fails
The cadence solves one adherence problem and leaves others untouched, which is worth stating because providers sometimes market the rhythm as though it solved everything.
Cost remains the dominant failure mode. KFF found that among adults who stopped taking a GLP-1, 14 percent cited cost. A majority of users described the medication as difficult to afford, including 55 percent of insured users, and about 27 percent held insurance and paid the full cost themselves. No cadence improves a budget.
Supply continuity is the second. A weekly rhythm is only an advantage if the medication is present each week. A shipment that arrives late converts an elegant cadence into an involuntary interruption, and the patient experiences that identically to having stopped.
The third is the one that is rarely designed for: travel. A weekly event has to survive time zones, luggage restrictions and temperature exposure. Patients who travel regularly encounter this early, and it is a common point at which treatment becomes irregular.
How it works in practice
Providers that take continuity seriously tend to build around the gaps rather than around the cadence itself, because the cadence takes care of itself and the gaps do not.
HealSend, a US telehealth service, lists compounded tirzepatide at 399 dollars per month and compounded semaglutide at 299 dollars per month, each as a once-weekly injection, with FedEx shipping in discreet, temperature-controlled packaging included in the monthly figure. Compounded medications are prepared by a licensed pharmacy for an individual patient; they are not approved by the FDA and do not go through its premarket review for safety, effectiveness or quality.
Patients begin with an online health profile reviewed by a US-licensed physician before any prescription is written, with eligibility determined by that physician. Treatment is open to adults aged 18 to 75 and is not for use during pregnancy. For patients considering tirzepatide injections on a sustained basis, the operational detail that matters most is that refills are coordinated so that patients do not run out. Plans are stated to be HSA and FSA eligible for reimbursement, and the company states that if its provider determines a GLP-1 medication is not right for a patient, the patient receives a full refund. The service operates across most, though not all, US states.
Refill coordination is unglamorous and it is the component most directly aligned with the way a weekly cadence actually fails. A patient does not usually decide to stop. A patient runs out.
What the adherence literature suggests transfers
Chronic-disease medicine has studied persistence for a long time, and several findings from other categories appear to transfer to this one.
The first is that early discontinuation is disproportionately common. Across many chronic therapies, the largest single drop in the treated population occurs within the first few months, before any long-term benefit could reasonably have accrued. The implication is that the design of the first eight to twelve weeks matters more than the design of the following year, because most of the attrition has already happened by then.
The second is that patients who experience an unplanned interruption frequently do not resume. An interruption breaks the behavioural pattern, and restarting requires an affirmative decision that reordering would not have required. This is why supply reliability and adherence are closer to the same variable than they appear.
The third is that perceived cost sensitivity rises over time rather than falling. A patient who accepted a price at the outset re-evaluates it monthly against competing demands, and the willingness to pay that justified starting does not automatically persist. Providers that treat the initial conversion as the hard part have the shape of the problem backwards.
What this implies for how programs should be built
Taken together, these suggest that the highest-leverage interventions are unglamorous: making sure the medication arrives before the previous supply runs out, keeping the price stable so that each month is not a fresh negotiation, and giving a patient somewhere to take a problem other than the cancellation page.
None of these require clinical innovation. They require treating continuity as a designed outcome rather than as something that either happens or does not.
What comes next for cadence
Oral formats change the trade-off rather than removing it
Oral formats in this class generally return to a daily rhythm. That is a meaningful trade: it removes the injection entirely, which matters a great deal to some patients, and it reintroduces the daily-adherence problem that weekly dosing had solved. Neither option dominates, and the right answer is patient-specific rather than general.
Longer intervals are being explored
Research into intervals beyond a week continues across the field. If a monthly cadence became practical it would change the adherence calculation again, and it would place even more weight on supply reliability, because a single missed shipment would represent a longer interruption.
The operational layer is where competition is moving
Every provider in this market offers broadly the same cadence because it is a property of the molecules rather than of the service. What differs is whether the medication reliably arrives, whether a patient can reach a clinician when something changes, and whether a planned pause is possible without cancelling.
The underlying point
A treatment that is theoretically effective and practically abandoned produces no clinical benefit. The weekly rhythm was a genuine advance because it moved a large population from a regimen they would not maintain to one they might.
Having solved the rhythm, the category’s remaining adherence problems are economic and logistical. Those are less interesting scientifically and more tractable operationally, which is a reasonable description of where the useful work in this field now sits.